scholarly journals Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases

Cancer ◽  
2020 ◽  
Vol 126 (19) ◽  
pp. 4341-4352
Author(s):  
Ariane Steindl ◽  
Sarah Yadavalli ◽  
Katharina‐Anna Gruber ◽  
Maria Seiwald ◽  
Brigitte Gatterbauer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Neurological Symptom ◽  
Symptom Burden ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung ◽  
Survival Prognosis

scholarly journals Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort

2019 ◽  
Vol 145 (1) ◽  
pp. 85-95 ◽  
Author(s):  
Ariane Steindl ◽  
Franziska Schlieter ◽  
Thomas Klikovits ◽  
Elena Leber ◽  
Brigitte Gatterbauer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real Life ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung ◽  
Prognostic Assessment

scholarly journals Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer

2020 ◽  
Author(s):  
Eric Nadler ◽  
Janet L Espirito ◽  
Melissa Pavilack ◽  
Bismark Baidoo ◽  
Ancilla Fernandes
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Service Use ◽  
Egfr Mutation ◽  
Symptom Burden ◽  
Small Cell ◽  
Small Cell Lung

Aim: To evaluate the real-world impact of brain metastases (BM) among patients with EGFR mutation-positive ( EGFRm) metastatic non-small-cell lung cancer (NSCLC). Materials & methods: This retrospective, observational matched cohort electronic health record study assessed adults with EGFRm metastatic NSCLC with/without BM. Results: Among 402 patients split equally between both cohorts (±BM), the majority were Caucasian (69%), female (65%) and with adenocarcinoma (92%). Overall symptom burden and ancillary support service use were higher and median overall survival from metastatic diagnosis was significantly shorter in BM patients (11.9 vs 16 months; p = 0.017). Conclusion: BM in EGFRm NSCLC patients can negatively impact clinical outcomes. New targeted therapies that can penetrate the blood–brain barrier should be considered for treating these patients.

Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan

Oncology ◽  
2020 ◽  
Vol 98 (7) ◽  
pp. 460-467
Author(s):  
Hironori Yoshida ◽  
Young Hak Kim ◽  
Shigeaki Iwatsubo ◽  
Chikara Sakaguchi ◽  
Yuichi Sakamori ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document